HRP20171908T1 - Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora - Google Patents

Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora Download PDF

Info

Publication number
HRP20171908T1
HRP20171908T1 HRP20171908TT HRP20171908T HRP20171908T1 HR P20171908 T1 HRP20171908 T1 HR P20171908T1 HR P20171908T T HRP20171908T T HR P20171908TT HR P20171908 T HRP20171908 T HR P20171908T HR P20171908 T1 HRP20171908 T1 HR P20171908T1
Authority
HR
Croatia
Prior art keywords
receptor ligands
pharmaceutical preparation
methods used
treatment methods
preparation containing
Prior art date
Application number
HRP20171908TT
Other languages
English (en)
Croatian (hr)
Inventor
Nika Adham
Gary Samoriski
Original Assignee
Richter Gedeon Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt. filed Critical Richter Gedeon Nyrt.
Publication of HRP20171908T1 publication Critical patent/HRP20171908T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20171908TT 2007-08-03 2008-08-04 Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora HRP20171908T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95369407P 2007-08-03 2007-08-03
PCT/US2008/072066 WO2009020897A1 (en) 2007-08-03 2008-08-04 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
EP08782602.0A EP2185155B1 (en) 2007-08-03 2008-08-04 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands

Publications (1)

Publication Number Publication Date
HRP20171908T1 true HRP20171908T1 (hr) 2018-01-26

Family

ID=40338740

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171908TT HRP20171908T1 (hr) 2007-08-03 2008-08-04 Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora

Country Status (20)

Country Link
US (3) US20090036468A1 (enExample)
EP (1) EP2185155B1 (enExample)
JP (1) JP5460594B2 (enExample)
KR (1) KR101612563B1 (enExample)
CN (1) CN101815519B (enExample)
AU (1) AU2008283989B2 (enExample)
CA (1) CA2695519A1 (enExample)
CY (1) CY1119828T1 (enExample)
DK (1) DK2185155T3 (enExample)
EA (1) EA018064B1 (enExample)
ES (1) ES2653852T3 (enExample)
HR (1) HRP20171908T1 (enExample)
HU (1) HUE036004T2 (enExample)
LT (1) LT2185155T (enExample)
MY (1) MY157192A (enExample)
NO (1) NO2185155T3 (enExample)
PL (1) PL2185155T3 (enExample)
PT (1) PT2185155T (enExample)
SI (1) SI2185155T1 (enExample)
WO (1) WO2009020897A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2317852T1 (sl) 2008-07-16 2015-04-30 Richter Gedeon Nyrt. Farmacevtske formulacije, ki vsebujejo ligande dopaminskega receptorja
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
JP5860457B2 (ja) 2010-06-18 2016-02-16 アルトス・セラピューティクス・リミテッド・ライアビリティ・カンパニーＡｌｔｏｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｌｌｃ Ｄ２アンタゴニスト、その合成方法および使用方法
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HUP1700253A1 (hu) * 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) * 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
EP4422629A4 (en) * 2021-10-28 2025-09-03 Richter Gedeon Nyrt TREATMENT OF MAJOR DEPRESSIVE DISORDER
JP2025500844A (ja) * 2021-12-13 2025-01-15 コンパス パスファインダー リミテッド 治療抵抗性うつ病の治療に使用するためのサイロシビン及び補助的セロトニン再取り込み阻害剤
CA3244202A1 (en) * 2022-03-17 2023-09-21 Mapi Pharma Ltd DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6556540B1 (en) * 1998-05-29 2003-04-29 Paradyne Corporation System and method for non-intrusive measurement of service quality in a communications network
SK287140B6 (sk) * 1999-10-25 2010-01-07 H. Lundbeck A/S Spôsob prípravy citalopramu a medziprodukt na jeho výrobu
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
US20040198809A1 (en) * 2001-05-01 2004-10-07 Connie Sanchez Use of enantiomeric pure escitalopram
WO2003086393A1 (en) * 2002-04-12 2003-10-23 Sepracor, Inc. 3-aza- and 1,4-diaza-bicyclo[4.3.0]nonanes, and methods of use thereof
DE60312874T2 (de) * 2002-06-20 2008-01-17 H. Lundbeck A/S Kombinationstherapie mit verwendung eines serotonin-wiederaufnahmehemmers
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EA200600531A1 (ru) * 2003-09-04 2006-08-25 Х. Лундбекк А/С Сочетание ингибитора обратного захвата серотонина и локсапина
HUP0500170A3 (en) * 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
HU230748B1 (hu) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása

Also Published As

Publication number Publication date
PL2185155T3 (pl) 2018-03-30
CN101815519B (zh) 2013-08-21
US20110015208A1 (en) 2011-01-20
AU2008283989A1 (en) 2009-02-12
US20120028991A1 (en) 2012-02-02
KR20100059830A (ko) 2010-06-04
CA2695519A1 (en) 2009-02-12
EP2185155A1 (en) 2010-05-19
KR101612563B1 (ko) 2016-04-14
HK1144784A1 (en) 2011-03-11
HUE036004T2 (hu) 2018-06-28
MY157192A (en) 2016-05-13
CN101815519A (zh) 2010-08-25
NO2185155T3 (enExample) 2018-03-03
SI2185155T1 (en) 2018-02-28
EA018064B1 (ru) 2013-05-30
ES2653852T3 (es) 2018-02-09
US20090036468A1 (en) 2009-02-05
JP5460594B2 (ja) 2014-04-02
LT2185155T (lt) 2017-12-11
WO2009020897A1 (en) 2009-02-12
EP2185155A4 (en) 2012-04-25
EA201000280A1 (ru) 2010-08-30
EP2185155B1 (en) 2017-10-04
PT2185155T (pt) 2018-01-04
DK2185155T3 (en) 2018-01-02
CY1119828T1 (el) 2018-06-27
JP2010535790A (ja) 2010-11-25
AU2008283989B2 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
HRP20171908T1 (hr) Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora
EA200971046A1 (ru) Новые соли пиперазина в качестве d/d-антагонистов
JP2014515013A5 (enExample)
HRP20130059T1 (hr) Derivati indolinona za lijeäśenje ili prevenciju fibroznih bolesti
JP2011148799A5 (enExample)
CY1119663T1 (el) Φαρμακευτικη μορφη δοσολογιας για απο του στοματος χορηγηση ενος αναστολεα της οικογενειας bcl-2
MX2014005635A (es) Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.
IN2014CN00408A (enExample)
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
MX2019009564A (es) Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino ) pirimidin-4-il) benzamida.
CY1118839T1 (el) Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη
JP2011524850A5 (enExample)
PH12016501310B1 (en) Pharmaceutical compositions comprising azd9291
HRP20120558T1 (hr) Kapa-selektivni antagonist opioidnih receptora
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
CY1112646T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1α
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN111032644A (zh) 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
DK2164492T3 (da) Trans-4-{2-[4-(2,3-dichlorphenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoylcyclohexylamin til behandling af skizofreni
CO2020000168A2 (es) Preparación sólida de cariprazina para administración oral
JP2012507535A5 (enExample)
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
HRP20210486T1 (hr) Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje primarnih negativnih simptoma shizofrenije
MX379558B (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3-il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino)-benzamida.
HRP20200662T1 (hr) Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak